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Introduction

Results

Inhaled Nitric Oxide (INO) and other pulmonary vasodilators, like
Flolan, have demonstrated positive physiological responses in select
patient populations; however, no clinical studies have proven any long
term outcome benefits in mortality and morbility1. However, INO and
Flolan are commonly used as rescue therapy in order to stabilize
critically ill patients until a more definitive treatment can be implemented
and future direction of care can be discussed with the family. Currently,
Lehigh Valley Health Network utilizes both drugs and has a titration
protocol for Flolan (fig 1) but not for INO (fig 2).

OBJECTIVES OF STUDY:
• Better assess the clinical outcomes of inhaled pulmonary
vasodilators.
• Determine if INO and Flolan are being administered correctly and for
the appropriate clinical indications.
• Streamline administration for their future utilization.

Methods
• A retrospective chart analysis of 158 patients (124 treated with Flolan and
34 patients treated with INO) was performed.
• The clinical indication, clinical response, and total drug administration
time was recorded.
• For the patients treated with Flolan it was noted if the prescribed titration
protocol was adhered to.
• A positive response was recorded if one or more of the following were
observed during treatment: an overall increase of 2% in SpO2, a 20%
increase in P/F ratio, an overall reduction of 10% in FiO2, a sustained
15% reduction in Mean Pulmonary Artery Pressure (MPAP), or if
hemodynamic support was reduced.
• A neutral response was recorded if none of the above changes were
observed.
• An unknown response was recorded if the changes could not be
determined secondary to treatment with either Flolan or INO.

Discussion

Flolan

INO

Mean time on drug

82.5 hours
Adjusted: 61.9 hours

37.5 hours

Median time on drug

41.5 hours
Adjusted: 39.6 hours

25.8 hours

Range of hours

0.75 – 663.2 hours

2.3 – 162.9 hours

Table 1: Time summaries for INO and Flolan. The “adjusted” times for Flolan are the
mean and median times calculated absent of data that was recorded two standard
deviations above or below the mean. 95% of data fell within +/– 2 standard
deviations.
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*Flolan protocol followed in 58% of cases

Fig. 1: Flolan Ventilator Set-Up

Fig. 2: INO
Ventilator Set-Up
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These results provide insight into how inhaled pulmonary
vasodilators are being administered at LVHN. According to the
data Flolan and INO are being used correctly and effectively at
LVHN, although there is opportunity for improvement.
• Of the 158 patients observed, all were treated for one of the
three clinical indications.
• The majority of patients had a positive clinical response to the
intervention.
• While the positive response rate recorded warrants the use of
these therapies, the titration protocol for Flolan was only
followed about half of the time it was used (58%). It is important
that the protocol be followed because it is in place to ensure that
patients do not react adversely to a sudden discontinuation of
the drug and to ensure that the lowest effective dose is
administered (which minimizes costs and potential side effects).
• Flolan had a positive response rate about 20% higher than INO;
although, it is possible that the small sample size for INO may
have contributed to this observation.
• Flolan is more affordable than INO and has fewer potential side
effects.
• Long term use of INO has been associated with
methemoglobinemia and increased bleeding risk2.

Conclusions about Future Care
1. Due to the lower cost of Flolan administration and the risks
associated with INO, Flolan should be used preferentially over
INO when possible.
2. Steps should be taken to ensure that the Flolan protocol is
followed more closely to optimize clinical outcomes and cost.
3. A titration protocol for INO should be implemented to optimize
clinical outcomes and cost.
By implementing these recommendations, the institution
may reduce costs, improve clinical outcomes, and increase
the effectiveness of inhaled pulmonary vasodilators.
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